Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
6.300
-0.300 (-4.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat
September 21, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected
September 21, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today?
September 21, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) announced
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 21, 2023
Via
Benzinga
Analyst Ratings for Travere Therapeutics
September 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Travere Therapeutics
August 18, 2023
Via
Benzinga
Earnings Scheduled For August 3, 2023
August 03, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Via
Benzinga
Expert Ratings for Travere Therapeutics
July 18, 2023
Via
Benzinga
Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
September 21, 2023
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know
September 19, 2023
Via
Benzinga
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
September 08, 2023
Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.
Via
Benzinga
3 Small-Cap Stocks That Could Be Big-Time Winners
July 22, 2023
These stocks come with significant risks. But they could generate huge returns over time.
Via
The Motley Fool
Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan
July 21, 2023
Travere Therapeutics shares have lost nearly 30% since early May.
Via
Talk Markets
Analyst Ratings for Travere Therapeutics
June 07, 2023
Via
Benzinga
11 Analysts Have This to Say About Travere Therapeutics
May 22, 2023
Via
Benzinga
Recap: Travere Therapeutics Q1 Earnings
May 04, 2023
Via
Benzinga
Earnings Outlook For Travere Therapeutics
May 03, 2023
Via
Benzinga
The Latest Analyst Ratings for Travere Therapeutics
April 17, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
July 21, 2023
Via
Benzinga
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation
July 17, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 17, 2023
Via
Benzinga
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
July 05, 2023
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.
Via
Investor's Business Daily
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
June 07, 2023
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.
Via
InvestorPlace
3 Biotech Stocks With Blockbuster Potential
May 24, 2023
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
May 22, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 02, 2023
Via
Benzinga
Chegg, Community Health Systems, Metropolitan Bank And Other Big Stocks Moving Lower On Tuesday
May 02, 2023
U.S. stocks traded lower, with the Dow Jones losing around 477 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Travere Crashes 29% On A Disappointing Update From A Two-Year Kidney Disease Test
May 02, 2023
Travere was testing a treatment for FSGS, a condition that causes kidney scarring.
Via
Investor's Business Daily
Travere Therapeutics' Rare Kidney Disease Drug Disappoints In Phase 3 Study, Analyst Says Efficacy Trends Suggest Potential Path Forward
May 02, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) announced
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 02, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.